# Fulcrum Therapeutics (FULC) — News

FULC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/fulc/news

## Recent headlines

- [Guyana's government reconsidering LNG project after Exxon Mobil told country it will need more gas for reinjection, sources say](https://www.ainvest.com/news/guyana-government-reconsidering-lng-project-exxon-mobil-told-country-gas-reinjection-sources-2610) — AInvest Wire, Oct 13, 2026
  Guyana’s government is reportedly reconsidering its liquefied natural gas (LNG) development plans after being informed by ExxonMobil that more gas will be required for reinjection to maintain pressure in offshore oil fields, according to sources familiar with the situation. This development adds to…
- [Fulcrum Therapeutics shares rise 3% after co to merge with Slate Medicines in all-stock deal](https://www.ainvest.com/news/fulcrum-therapeutics-shares-rise-3-merge-slate-medicines-stock-deal-2608) — AInvest Wire, Aug 17, 2026
- [Fulcrum Therapeutics, combined company cash expected to fund Slate's operations into 2029](https://www.ainvest.com/news/fulcrum-therapeutics-combined-company-cash-expected-fund-slate-operations-2029-2608) — AInvest Wire, Aug 17, 2026
- [Fulcrum Therapeutics shares down 3.2% after the bell; filing shows co approves restructuring plan after discontinuing Pociredir for sickle cell disease](https://www.ainvest.com/news/fulcrum-therapeutics-shares-3-2-bell-filing-shows-approves-restructuring-plan-discontinuing-pociredir-sickle-cell-disease-2606) — AInvest Wire, Jun 4, 2026
  Fulcrum Therapeutics (Nasdaq: FULC) shares fell 3.2% in after-hours trading following the company’s announcement that it has discontinued its lead clinical program , pociredir, for the treatment of sickle cell disease (SCD) and has initiated a strategic review of its options. The decision comes…
- [Fulcrum Therapeutics - workforce reduction communicated June 4, 2026; charges to be incurred in Q2 2026 - SEC filing](https://www.ainvest.com/news/fulcrum-therapeutics-workforce-reduction-communicated-june-4-2026-charges-incurred-q2-2026-sec-filing-2606) — AInvest Wire, Jun 4, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).